In 2025, Alnylam Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Alnylam Pharmaceuticals has also provided a category-level breakdown for 9 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 6,785a | 3,831a | 3,546a | |
Total Scope 2 | ||||
Market-Based | 8,499a | 8,028a | 9,918a | |
Location-Based | 10,214a | 9,687a | 9,898a | |
Total Scope 3 | 161,533.49a | 160,378.2a | 151,376b | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 1.8269a | 1.704a | 1.9395a |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Alnylam Pharmaceuticals amounted to 16,999 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Alnylam Pharmaceuticals increased by 25.75%, suggesting that the company faced challenges in reducing its emissions from its core operations.a
In 2025, the total Scope 1 emissions of Alnylam Pharmaceuticals were 6,785 metric tons of CO₂ equivalent (tCO₂e).a
Since 2020, Alnylam Pharmaceuticals's Scope 1 emissions have increased by 122.17%, reflecting a rising long-term trend in Scope 1 emissions over time.ac
Compared to the previous year (2024), Alnylam Pharmaceuticals's Scope 1 emissions increased by 77.11%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a
In 2025, Alnylam Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 8,499 tCO₂e using the market-based method and 10,214 tCO₂e using the location-based method.a
Since 2020, Alnylam Pharmaceuticals's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have increased by 19.91%, reflecting a rising long-term trend in Scope 2 emissions over time.ac
Compared to the previous year (2024), Alnylam Pharmaceuticals's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Alnylam Pharmaceuticals's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2025, Alnylam Pharmaceuticals reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2025, Alnylam Pharmaceuticals reported 161,533.49 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2025 disclosure of Alnylam Pharmaceuticals includes a breakdown across 9 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2024, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2025, Alnylam Pharmaceuticals reported total Scope 3 emissions of 161,533.49 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.a
Since 2020, Alnylam Pharmaceuticals's Scope 3 emissions have increased by 5,171.98%, reflecting a rising long-term trend in Scope 3 emissions over time.ac
Compared to the previous year (2024), Alnylam Pharmaceuticals's Scope 3 emissions remained relatively stable, indicating that Alnylam Pharmaceuticals's emissions have plateaued with no significant change in its value chain footprint.a
In 2025, Alnylam Pharmaceuticals reported emissions for 9 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This partial disclosure allows for some insight into the company's indirect impacts.
In 2025, the largest contributors to Alnylam Pharmaceuticals's Scope 3 emissions were:a
In 2025, Alnylam Pharmaceuticals reported Scope 1 greenhouse gas (GHG) emissions of 6,785 tCO₂e and total revenues of USD 3,714 millions. This translates into an emissions intensity of 1.83 tCO₂e per millions USD.a
In 2025, Alnylam Pharmaceuticals reported a Scope 1 emissions intensity of 1.83 tCO₂e per millions USD. Compared to the peer group median of 2.76, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2025, Alnylam Pharmaceuticals ranked 9 out of 21 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
Alnylam Pharmaceuticals is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a
In 2025, Alnylam Pharmaceuticals reported a total carbon footprint of 178,532.49 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 2.67% increase compared to 2024, suggesting a rise in emissions across its operations or value chain.a
The largest contributor to Alnylam Pharmaceuticals's total carbon footprint was Scope 3 emissions, accounting for 90.48% of the company's total carbon footprint, followed by Scope 2 emissions at 5.72%.a